Albiglutide is a glucagon-like peptide-1
agonist drug marketed by GlaxoSmithKline for treatment of type 2 diabetes. It is
a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to
human albumin. The drug was invented by Human Genome Sciences and was developed
in collaboration with GSK. Albiglutide has a half-life of four to
seven days, which is considerably longer than the other two GLP-1 analogs
approved for market use, exenatide and liraglutide. GLP-1 drugs are currently
only available for subcutaneous administration on a daily basis, so a
GLP-1 drug with a longer half-life is desirable. Such a drug would only need
to be injected biweekly or weekly instead of daily, reducing the
discomfort and inconvenience of GLP-1 administration considerably.
It has not yet been determined whether albiglutide is as effective an
antidiabetic agent as GLP-1 drugs currently on the market, and final data
remains to be published regarding the incidence of adverse effects related to
the drug. To evaluate the efficacy and safety of the drug, albiglutide is
undergoing eight Phase III clinical trials. Four of these trials should
report useful data by end 2010.6 GSK filed for FDA approval on 012013 and
European Medical Agency on 032013. On 082013 GSK released a press release
pushing the marketing date 3 months to 042014.
In March 2014, GlaxoSmithKline PLC received approval from the European
Commission to market albiglutide under the name ‘Eperzan’.
In April 2014, the FDA approved albiglutide under the name Tanzeum.
See also Glucagon-like peptide-1 analogs:
taspoglutide DPP4 inhibitors